753924-40-2Relevant articles and documents
Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain
Luo, Guanglin,Chen, Ling,Easton, Amy,Newton, Amy,Bourin, Clotilde,Shields, Eric,Mosure, Kathy,Soars, Matthew G.,Knox, Ronald J.,Matchett, Michele,Pieschl, Rick L.,Post-Munson, Debra J.,Wang, Shuya,Herrington, James,Graef, John,Newberry, Kimberly,Sivarao, Digavalli V.,Senapati, Arun,Bristow, Linda J.,Meanwell, Nicholas A.,Thompson, Lorin A.,Dzierba, Carolyn
, p. 831 - 856 (2019/01/21)
3-Aryl-indole and 3-aryl-indazole derivatives were identified as potent and selective Nav1.7 inhibitors. Compound 29 was shown to be efficacious in the mouse formalin assay and also reduced complete Freund's adjuvant (CFA)-induced thermal hyper
PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2
-
Paragraph 0239; 0240, (2018/05/03)
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these
GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT
-
Paragraph 585-587, (2014/05/24)
The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.
